Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 40-Week, Phase 4, Double-Blind, Placebo-Controlled, Multicenter, Randomized-Withdrawal Study to Evaluate the Long-Term Efficacy and Safety of KAPVAY™ (Clonidine Hydrochloride) Extended-Release in Children and Adolescents With ADHD

NCT01439126 is registered in ClinicalTrials.gov with Concordia Pharmaceuticals Inc., Barbados as lead sponsor.

NCT NCT01439126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01439126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 40-Week, Phase 4, Double-Blind, Placebo-Controlled, Multicenter, Randomized-Withdrawal Study to Evaluate the Long-Term Efficacy and Safety of KAPVAY™ (Clonidine Hydrochloride) Extended-Release in Children and Adolescents With ADHD
Lead sponsor
Concordia Pharmaceuticals Inc., Barbados
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2011
Completion date
October 31, 2012
Enrollment
135 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder